In this preliminary trial, adding polymyxin B hemoperfusion filter to conventional therapy for treating patients in septic shock improved hemodynamics and lowered 28-day mortality within 6 hours of abdominal surgery.
Early Activity in ICU Improves Exercise Capacity, Muscle Force at Discharge

Early Exercise in Critically Ill Patients Enhances Short-Term Functional Recovery.
Burtin C, Clerckx B, et al: Crit Care Med 2009; 37 (September): 2499 37 (September): -2505 Early mobilization in critically ill patients holds promise as a measure to prevent critical illness polyneuropathy.
Background: Critical illness polyneuropathy (CIPN) is the most common peripheral neuromuscular disorder in the ICU. Characterized by symmetric proximal muscle weakness, CIPN is associated with prolonged mechanical ventilation and need for rehabilitation. Early activity in immobilized patients may curb or minimize development of CIPN. Objective: To determine whether a daily exercise session with bedside cycle ergometer prevents or attenuates the decrease in functional exercise capacity, functional status, and quadriceps force in ICU patients with prolonged lengths of stay. Design: Single-center, randomized controlled trial. Participants: 90 patients admitted to surgical and medical ICUs for at least 5 days who had an expected stay of at least 7 more days were eligible for inclusion. Patients were included as soon as their cardiopulmonary condition allowed bedside cycling exercise. Methods: Both groups underwent standard respiratory physiotherapy and daily passive or active motion sessions in upper and lower limbs. The treatment group also performed 20 minutes of passive or active bedside cycling per day. The primary outcome was 6-minute walk distance (6MWD) at hospital discharge. Secondary outcomes included quadriceps force and functional status. Data on weaning time, length of stay, and 1-year mortality were also collected. Results: Of 90 patients randomized, 32 control patients and 26 treatment patients had full data collection. The majority of patients (n=71) were recruited from surgical ICUs. Both groups were well matched for baseline characteristics and ICU therapies, although the treatment group had a longer period of IV sedation (11 vs 8 days; P <0.05). 6MWD was higher in the treatment group than in the control group (196 vs 143 minutes; P <0.05). Short Form 36 Health Survey questionnaire results and quadriceps force were also higher at hospital discharge in the treatment group. Weaning time, ICU and hospital lengths of stay, and 1-year mortality did not differ between groups. Conclusions: Early exercise training with bedside cycle ergometer in critically ill ICU patients with a prolonged length of stay improved functional exercise capacity, self-perceived functional status, and quadriceps strength at hospital discharge. Reviewer's Comments: This study demonstrates that early activity in ICU patients may minimize development of CIPN, and it represents the first randomized trial to address this hypothesis in an ICU population. Although limited by the lack of objective measures of exercise intensity, standardized post-ICU rehabilitation, and formal electrophysiologic diagnosis of CIPN, the authors have provided the framework for larger studies to investigate preventive measures for minimizing development of CIPN. (Reviewer-M. Bradley Drummond, MD). Ticagrelor, a new ADP platelet receptor antagonist, is promising as treatment in acute coronary syndrome.
New Antiplatelet Therapies Promising in ACS
Background: Randomized trials have established dual antiplatelet therapy with aspirin and clopidogrel as standard of care for acute coronary syndrome (ACS). Recent clinical trials have evaluated new platelet ADP antagonists in ACS patients. Clopidogrel, a prodrug, is extensively metabolized by the hepatic P450 system. Genetically slow metabolizers make a less-active drug and have a greater risk for recurrent ischemic events and stent thrombosis. Onset of action for clopidogrel is several hours, which may be an issue in ACS. Lastly, clopidogrel permanently inhibits the platelet ADP P2Y12 receptor, thereby increasing bleeding risk if patients require urgent coronary artery bypass surgery. Ticagrelor is a reversible, oral antagonist of the platelet P2Y12 ADP receptor with a faster onset of action and more consistent platelet inhibition compared to clopidogrel. Objective: To compare ticagrelor with clopidogrel in preventing recurrent ischemic events. Design: Randomized double-blind study. Participants: 18,624 ACS patients with high-risk ST-segment elevation myocardial infarction (STEMI) or non-STEMI. Methods: Patients received ticagrelor, 180-mg load followed by 90 mg twice daily, or clopidogrel, 300-mg load followed by 75 mg daily. All patients received aspirin and standard ACS therapies. The primary end point was time to vascular death, myocardial infarction, or stroke at 12 months. Major life-threatening bleeding was also prospectively evaluated. Results: In this large trial, the ticagrelor and clopidogrel groups were well matched. Approximately 38% of patients had STEMI. The primary end point at 12 months occurred significantly less often in the ticagrelor group (9.8%) compared to the clopidogrel group (11.7%). This difference was apparent within 30 days and persisted throughout 1 year of follow-up. Secondary individual end points of myocardial infarction, vascular death, death from any cause, and stent thrombosis were significantly less in ticagrelor patients. Hemorrhagic stroke tended to be greater in patients randomized to ticagrelor (0.3%) compared to those receiving clopidogrel (0.2%; P =0.06). Overall, rates of major hemorrhage were similar. Conclusions: Ticagrelor is superior to clopidogrel in preventing vascular death, myocardial infarction, and death over 12 months, without an increase in major bleeding. Reviewer's Comments: Dual antiplatelet therapy with aspirin plus clopidogrel is superior to aspirin alone in ACS patients. New ADP antagonists may replace clopidogrel in certain situations. Prasugrel offers greater platelet inhibition than does clopidogrel, with greater prevention of ischemic events but more bleeding than clopidogrel in ACS patients. Ticagrelor has certain favorable pharmacologic features. First, it gives more complete platelet inhibition and more rapid onset of action compared to clopidogrel. This may explain the superiority of ticagrelor in the PLATO trial. It is completely reversible, making its use attractive prior to knowledge of the coronary anatomy and in those who require non-cardiac surgery with a stent already in place. (Reviewer-Steven P. Schulman, MD). Transfusion in anemic patients after subarachnoid hemorrhage may minimize cerebral ischemia, although this strategy cannot be recommended without further clinical studies.
RBC Transfusion Improves Cerebral DO 2 in Anemic SAH Patients
Red Blood Cell Transfusion Increases Cerebral Oxygen Delivery in Anemic Patients With Subarachnoid Hemorrhage.
Background: A critical reduction in oxygen delivery (DO 2 ) underlies cerebral ischemia. After subarachnoid hemorrhage (SAH), anemia is common, may worsen DO 2 , and may place vulnerable brain regions at greater risk for ischemia. Objective: To test the hypothesis that transfusion increases oxygen delivery to regions at risk for ischemia. Participants: 8 patients with spontaneous SAH who had a secured aneurysm, had a hemoglobin level <10 g/dL, and were at risk for delayed cerebral ischemia (DCI). Methods: 15O-labeled PET was performed to measure cerebral blood flow (CBF), DO 2 , oxygen extraction fraction (OEF), and cerebral metabolic rate of oxygen (CMRO 2 ) before and after transfusion of 1 unit of packed red blood cells (RBCs). Regional analysis focused on regions with vasospasm and with baseline oligemia (reduced DO 2 and elevated OEF). Results: RBC transfusion caused a 15% rise in both hemoglobin (8.7 to 10.0 g/dL) and oxygen content. Mean global CBF did not change after transfusion. Oxygen delivery increased by almost 20% and was associated with a fall in OEF from 48.7% to 41.0% with stable CMRO 2 . Mean cerebral blood volume was unchanged. In regions with oligemia, oxygen delivery improved to a greater extent than in non-oligemic regions, and the decrease in OEF was larger. No rise in CMRO 2 was seen. Regions with vasospasm had an attenuated response to transfusion. The increase in delivery after transfusion was smaller (10% vs 24%), although reduction in OEF was similar, corresponding to a 7% decrease in CBF. Only 57% of vasospastic regions resolved after transfusion, compared to 85% of such regions without vasospasm. Conclusions: RBC transfusion in anemic patients with SAH significantly increases cerebral DO 2 while reducing OEF and without lowering global CBF. Reviewer's Comments: This small study suggests that, in the acute phase, raising hemoglobin in patients with SAH may have similar benefits to augmenting CBF through other measures. Transfusion increased arterial oxygen content, but not at the expense of CBF. This indicates that cerebral blood vessels did not vasoconstrict in response to higher arterial oxygen content. In regions with vasospasm, oxygen delivery still rose, but it was attenuated and associated with a decrease in CBF. This suggests that higher viscosity may impair flow when flow is already reduced and compensatory vasodilation is not possible. The main limitation of the study is that only the immediate response to transfusion was measured and not longer-term effects. The effect of RBC storage time also needs further study. At this time, the optimal hemoglobin level in patients with SAH is uncertain. (Reviewer-Wendy C. Ziai, MD).
Either Heparin, Antiplatelet Tx Reduces Stroke After BCVIs
Treatment for Blunt Cerebrovascular Injuries: Equivalence of Anticoagulation and Antiplatelet Agents. Cothren CC, Biffl WL, et al: Arch Surg 2009; 144 (July): 685-690 Antiplatelet agents may be equal to anticoagulation for stroke prevention after closed head trauma.
Background: Systemic heparin has been the treatment of choice after blunt cerebrovascular injuries (BCVIs) to prevent devastating injury-related strokes. Recent studies suggest that antiplatelet agents may be more efficacious. Design: Retrospective review of a prospective database at a Level I regional trauma center. Participants: Patients with BCVIs from 1997 to 2007. Methods: The main outcome measure was the incidence of cerebrovascular accidents (CVAs) in each treatment arm. Results: 422 BCVIs were identified in 301 patients during this 10-year study period. Of patients, 64.8% were men, average age was 37.0 years, and mean injury severity score was 27.0. Twenty-two patients presented with neurologic ischemia, and 5 sustained CVAs after embolization and/or stenting of an injury. In 282 asymptomatic BCVIs, treatment was started with heparin in 192, aspirin in 67, and aspirin and/or clopidogrel in 23. One patient had a stroke (0.5%). Of 107 patients with untreated, asymptomatic BCVIs, 23 (21.5%) had a stroke. Mean time to diagnosis was 58 hours in untreated patients sustaining BCVI-related CVAs. In patients who did not show signs of symptoms within 2 hours of injury, mean time to CVA diagnosis was 75 hours. Injury healing rates (heparin, 39%; aspirin, 43%; aspirin/clopidogrel, 46%) and injury progression rates (12%, 10%, 15%, respectively) were equivalent between regimens. Conclusions: With an overall stroke risk of 21% and a documented latent period, comprehensive screening, early diagnosis, and institution of antithrombotic therapy for BCVI are clearly justified. Type of treatment (heparin vs antiplatelet agents) does not appear to affect stroke risk or injury healing rates. Reviewer's Comments: While the subset of patients in whom anticoagulation is contraindicated might benefit from antiplatelet agents, such a patient would be rare as most patients with such contraindications would not allow either therapy. Measuring and documenting adequate antiplatelet therapy causes additional challenges. The downside of antiplatelet agents and possible resultant intracranial hemorrhage may outweigh any benefit for those patients at greatest risk. While it might be more practical to use heparin in the acute phase of the early hospital course, there may be some benefit in prescribing antiplatelet agents as patients are prepared for discharge. (Reviewer-I. Michael Leitman, MD).
